Geron Corporation
(NASDAQ : GERN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading GERN News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.61%82.771.8%$750.17m
BIIBBiogen Inc.
0.28%239.581.0%$576.50m
CELGCelgene Corporation
-0.51%98.311.2%$471.22m
AMGNAmgen Inc.
0.73%151.201.0%$445.34m
REGNRegeneron Pharmaceuticals, Inc.
0.20%348.563.1%$328.52m
ALXNAlexion Pharmaceuticals, Inc.
0.69%114.962.5%$299.20m
ILMNIllumina, Inc.
0.14%137.774.9%$165.52m
VRTXVertex Pharmaceuticals Incorporated
1.24%86.052.6%$135.22m
MDVNMedivation, Inc.
-0.43%60.692.8%$131.77m
BMRNBioMarin Pharmaceutical Inc.
0.59%78.834.0%$128.99m
TSROTESARO, Inc.
8.33%83.8515.8%$122.66m
SRPTSarepta Therapeutics, Inc.
1.07%18.8649.4%$107.05m
AAgilent Technologies, Inc.
0.67%44.061.0%$103.58m
CPXXCelator Pharmaceuticals, Inc.
0.00%30.218.5%$102.09m
EXASExact Sciences Corporation
10.84%12.5121.4%$99.66m

Company Profile

Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.